Deutsche Bank AG reduced its holdings in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) by 43.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 307,769 shares of the company’s stock after selling 237,820 shares during the period. Deutsche Bank AG’s holdings in Evolus were worth $3,398,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Tri Locum Partners LP purchased a new stake in shares of Evolus in the fourth quarter valued at about $8,198,000. Gilder Gagnon Howe & Co. LLC raised its holdings in Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock valued at $7,753,000 after acquiring an additional 520,859 shares in the last quarter. Caligan Partners LP grew its position in shares of Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after buying an additional 498,900 shares during the last quarter. Allostery Investments LP bought a new position in shares of Evolus in the fourth quarter valued at approximately $4,760,000. Finally, Altium Capital Management LLC boosted its holdings in Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock worth $7,562,000 after buying an additional 330,000 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
EOLS has been the topic of a number of recent research reports. BTIG Research started coverage on shares of Evolus in a report on Thursday, April 17th. They set a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Barclays raised their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus presently has an average rating of “Buy” and a consensus price target of $23.75.
Insider Buying and Selling
In related news, insider David Moatazedi sold 15,787 shares of the company’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $155,817.69. Following the completion of the sale, the insider now directly owns 492,832 shares in the company, valued at $4,864,251.84. This represents a 3.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Rui Avelar sold 27,904 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. This trade represents a 7.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,241 shares of company stock worth $1,048,666. 5.90% of the stock is owned by corporate insiders.
Evolus Stock Performance
Shares of EOLS stock opened at $9.96 on Wednesday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $642.18 million, a price-to-earnings ratio of -10.94 and a beta of 1.11. The stock has a fifty day moving average of $11.19 and a 200 day moving average of $12.24. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82.
Evolus Company Profile
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
- Five stocks we like better than Evolus
- Overbought Stocks Explained: Should You Trade Them?
- Top 5 Stocks Hedge Funds Are Buying Right Now
- A Deeper Look at Bid-Ask Spreads
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- There Are Different Types of Stock To Invest In
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS – Free Report).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.